Accord Healthcare has acquired Essential Pharmaceuticals, a New Jersey company that provides products, services and contributions to transplant medicine.
The acquisition gives Accord the rights to sell Custodiol HTK Solution, a leading organ preservation solution.
"We are thrilled to be expanding on our capabilities of providing life-saving, affordable medicines and therapies to patients and health care providers alike,” Gerald Price, president of Accord Healthcare, said in a statement. “Custodiol HTK is a vital product in the organ donation process and we are excited to include it in our product offering, as well as build upon the research and development programs in place for future organ preservation drug products.”
Custodiol HTK is used for perfusion and flushing of donor kidneys, liver, pancreas and heart before the organ is given to a patient.
"As a growth oriented company, we couldn't have found a better partner than Accord Healthcare,” Allan Weber, former CEO of Essential, said. “Valued Custodiol HTK customers can expect to see the same familiar faces of our transplant specialists, as well as experience the same outstanding customer service to which they have grown accustomed."